Characteristics of pericardial effusions in patients with leukemia

Cancer

Volumn 116, Issue 10, 2010, Pages 2366-2371

  Sampat, Keeran ^a   Rossi, Adriana ^b   Garcia Gutierrez, Valentin ^c   Cortes, Jorge ^a   Pierce, Sherry ^a   Kantarjian, Hagop ^a   Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Histone deacetylase inhibitors; Leukemia; Myelodysplastic syndrome; Pericardial effusions

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ARSENIC TRIOXIDE; ASPARAGINASE; DNA TOPOISOMERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; VINCA ALKALOID; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; ECHOCARDIOGRAPHY; HUMAN; INCIDENCE; LEUKEMIA; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PERICARDIAL EFFUSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; ADOLESCENT; ADULT; AGED; ASCITES; FEMALE; MALE; MIDDLE AGED; MORTALITY; PLEURA EFFUSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASCITES; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; PERICARDIAL EFFUSION; PLEURAL EFFUSION;

EID: 77952560069     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24946     Document Type: Article

References (9)

1. Roberts WC, Bodey GP, Wertlake PT. The heart in acute leukemia. A study of 420 autopsy cases. Am J Cardiol. 1968; 21:388-412.
2. Arya LS, Narain S, Thavaraj V, Saxena A, Bhargava M. Leukemic pericardial effusion causing cardiac tamponade. Med Pediatr Oncol. 2002;38:282-284. (Pubitemid 34258426)
3. Bierman HR, Perkins EK, Ortega P. Pericarditis in patients with leukemia. Am Heart J. 1952;43:413-422.
4. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23:7685-7696.
5. Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet. 2004;363:717-727.
6. Siu LL, Pili R, Duran I, et al. Phase I study of MGCD0103 given as a 3-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol. 2008; 26:1940-1947.
7. Crump M, Andreadis C, Assouline S, et al. Younes treatment of relapsed or refractory non-Hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study [abstract]. J Clin Oncol. 2008;26(suppl). Abstract 8528.
8. Le Tourneau C, Siu LL. Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. Expert Opin Investig Drugs. 2008;17:1247-1254.
9. Rasheed W, Bishton M, Johnstone RW, Prince HM. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther. 2008;8:413-432. (Pubitemid 351836289)